639 related articles for article (PubMed ID: 37121515)
1. Multi-targeted immunotherapeutics to treat B cell malignancies.
Gambles MT; Yang J; Kopeček J
J Control Release; 2023 Jun; 358():232-258. PubMed ID: 37121515
[TBL] [Abstract][Full Text] [Related]
2. Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells.
Yong SB; Chung JY; Song Y; Kim J; Ra S; Kim YH
Biomaterials; 2019 Oct; 219():119401. PubMed ID: 31398571
[TBL] [Abstract][Full Text] [Related]
3. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
Pennock GK; Chow LQ
Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281
[TBL] [Abstract][Full Text] [Related]
4. CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies.
Shanehbandi D; Majidi J; Kazemi T; Baradaran B; Aghebati-Maleki L
Curr Cancer Drug Targets; 2017; 17(5):423-444. PubMed ID: 28067179
[TBL] [Abstract][Full Text] [Related]
5. Recent Advances in Stimuli-Responsive Platforms for Cancer Immunotherapy.
Li L; Yang Z; Chen X
Acc Chem Res; 2020 Oct; 53(10):2044-2054. PubMed ID: 32877161
[TBL] [Abstract][Full Text] [Related]
6. T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy.
Sackstein R; Schatton T; Barthel SR
Lab Invest; 2017 Jun; 97(6):669-697. PubMed ID: 28346400
[TBL] [Abstract][Full Text] [Related]
7. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
8. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
9. Noncoding RNAs as novel immunotherapeutic tools against cancer.
Kaur M; Kaur B; Konar M; Sharma S
Adv Protein Chem Struct Biol; 2022; 129():135-161. PubMed ID: 35305717
[TBL] [Abstract][Full Text] [Related]
10. Engineering nanoparticle strategies for effective cancer immunotherapy.
Yoon HY; Selvan ST; Yang Y; Kim MJ; Yi DK; Kwon IC; Kim K
Biomaterials; 2018 Sep; 178():597-607. PubMed ID: 29576282
[TBL] [Abstract][Full Text] [Related]
11. Natural killer cell-based strategies for immunotherapy of cancer.
Vaněk O; Kalousková B; Abreu C; Nejadebrahim S; Skořepa O
Adv Protein Chem Struct Biol; 2022; 129():91-133. PubMed ID: 35305726
[TBL] [Abstract][Full Text] [Related]
12. Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies.
Tsirigotis P; Savani BN; Nagler A
Ann Med; 2016 Sep; 48(6):428-439. PubMed ID: 27224873
[TBL] [Abstract][Full Text] [Related]
13. Immunoreceptor Engineering and Synthetic Cytokine Signaling for Therapeutics.
Scheller J; Engelowski E; Moll JM; Floss DM
Trends Immunol; 2019 Mar; 40(3):258-272. PubMed ID: 30738638
[TBL] [Abstract][Full Text] [Related]
14. Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade.
Heath BR; Michmerhuizen NL; Donnelly CR; Sansanaphongpricha K; Sun D; Brenner JC; Lei YL
J Dent Res; 2019 Sep; 98(10):1073-1080. PubMed ID: 31340724
[TBL] [Abstract][Full Text] [Related]
15. Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies.
Biagi E; Marin V; Giordano Attianese GM; Dander E; D'Amico G; Biondi A
Haematologica; 2007 Mar; 92(3):381-8. PubMed ID: 17339188
[TBL] [Abstract][Full Text] [Related]
16. T-cell-based immunotherapy in colorectal cancer.
Feng M; Zhao Z; Yang M; Ji J; Zhu D
Cancer Lett; 2021 Feb; 498():201-209. PubMed ID: 33129958
[TBL] [Abstract][Full Text] [Related]
17. Neoantigens - the next frontier in precision immunotherapy for B-cell lymphoproliferative disorders.
Sabdia MB; Patch AM; Tsang H; Gandhi MK
Blood Rev; 2022 Nov; 56():100969. PubMed ID: 35570070
[TBL] [Abstract][Full Text] [Related]
18. Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies.
Falchi L
Curr Hematol Malig Rep; 2017 Oct; 12(5):484-494. PubMed ID: 28822058
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia.
Knaus HA; Kanakry CG; Luznik L; Gojo I
Curr Drug Targets; 2017; 18(3):315-331. PubMed ID: 25981611
[TBL] [Abstract][Full Text] [Related]
20. An overview of cancer immunotherapeutic strategies.
Wahid B; Ali A; Rafique S; Waqar M; Wasim M; Wahid K; Idrees M
Immunotherapy; 2018 Aug; 10(11):999-1010. PubMed ID: 30149763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]